Free Trial

Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Passes Above Fifty Day Moving Average - What's Next?

Elite Pharmaceuticals logo with Medical background

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report) shares passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.57 and traded as high as $0.62. Elite Pharmaceuticals shares last traded at $0.62, with a volume of 1,084,598 shares trading hands.

Elite Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.08, a current ratio of 4.88 and a quick ratio of 3.50. The company has a 50-day moving average of $0.57 and a 200-day moving average of $0.51.

Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last issued its quarterly earnings data on Monday, June 30th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a positive return on equity of 3.96% and a negative net margin of 5.13%. The business had revenue of $32.00 million during the quarter.

About Elite Pharmaceuticals

(Get Free Report)

Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Elite Pharmaceuticals Right Now?

Before you consider Elite Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.

While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines